Technology
Health
Pharmaceutical

Celyad

$19.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.34 (-1.76%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Celyad and other stocks, options, ETFs, and crypto commission-free!

About

Celyad SA American Depositary Shares, also called Celyad, is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. Read More The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Employees
96
Headquarters
Mont-Saint-Guibert, Walloon Region
Founded
2007
Market Cap
229.05M
Price-Earnings Ratio
Dividend Yield
Average Volume
7.04K
High Today
$19.94
Low Today
$19.18
Open Price
$19.88
Volume
308.00
52 Week High
$32.18
52 Week Low
$15.36

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Cancer Prevention
2015 IPO
Europe (Non-UK)

News

NasdaqMay 9

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 09, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced an update on operational developments for the first quarter ended March 31, 2019. "We began the year with the announcement that treatment with CYAD-01 demonstrated a 40% complete response rate in patients with relapsed/refractory acute myeloid leukemia. As we continue to advan...

11
Yahoo FinanceMay 2

Celyad Announces May 2019 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, May 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that management plans to attend the following events in May 2019: Conference details: 5th Annual SunTrust Robinson Humphrey (STRH) Life Sciences Summit Date: Wednesday, May 8, 2019 Location: New York, NY CAR-T and The Rise of the Cellicon Valley Date: Friday, May 10, 201...

5

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.